@Article{096504022X16427607626672,
AUTHOR = {Shuai Liu, Lu Lu, Feng Pan, Chunsheng Yang, Jing Liang, Jinfeng Liu, Jian Wang, Rong Shen, Fu-Ze Xin, Nan Zhang},
TITLE = {Real-World Data: Fruquintinib in Treating Metastatic Colorectal Cancer},
JOURNAL = {Oncology Research},
VOLUME = {29},
YEAR = {2021},
NUMBER = {1},
PAGES = {25--31},
URL = {http://www.techscience.com/or/v29n1/48450},
ISSN = {1555-3906},
ABSTRACT = {Fruquintinib, also called HMPL-013, was first discovered by Hutchison Whampoa Pharmaceuticals Co. Ltd., 
Shanghai, China, and it is an oral vascular endothelial growth factor receptor (VEGFR) inhibitor. In clinical trials, fruquintinib has demonstrated a survival benefit in metastatic colorectal cancer (mCRC) patients. The purpose of this study was to retrospectively evaluate the efficacy and toxicity of fruquintinib in real-world patients.
We collected data from patients with mCRC treated with oral fruquintinib from 2018 to 2020 in six different 
institutions. Patients with mCRC initially received 5 mg of oral fruquintinib daily for 3 weeks. Progression-free 
survival (PFS) was evaluated using the Kaplan–Meier method. The efficacy and safety of fruquintinib were 
also assessed. Seventy-five patients were involved in our study, and 29.3% of patients achieved stable disease 
(SD). Median PFS was 5.4 months (95% CI: 4.841–5.959). The treatment-emergent adverse events (TEAEs) 
with fruquintinib were acceptable with grade 3 TEAEs of 6%. The grade 3 TEAEs were hand–foot skin reaction (HFSR), fatigue, and stomatitis. The ECOG performance status was associated with PFS. In this real-world 
study, the clinical activity of fruquintinib was consistent with what has been reported in previous clinical trials. 
The level of safety was acceptable, and the side effects were manageable.},
DOI = {10.3727/096504022X16427607626672}
}